Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SIM0715
- Development stage
- Preclinical
- Lead developer
- Simcere Pharmaceutical Group
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
01
Overview
SIM0715 is an investigational proteolysis-targeting chimera (PROTAC) developed by Simcere Pharmaceutical (Jiangsu Xiansheng) for the treatment of autoimmune disorders. It is designed to specifically target and induce the proteasomal degradation of Signal Transducer and Activator of Transcription 6 (STAT6). STAT6 is a critical transcription factor in the IL-4 and IL-13 signaling pathways, which are primary drivers of Type 2 (Th2) immune responses. By degrading STAT6 rather than simply inhibiting its activity, SIM0715 aims to provide a more potent and durable suppression of inflammatory signaling, offering a potential therapeutic approach for conditions such as atopic dermatitis, asthma, and other Th2-mediated autoimmune diseases.
- Other names
- STAT6 PROTACSTAT-6 PROTACSTAT 6 PROTACSTAT6 degraderSTAT-6 degraderSTAT 6 degrader
02
Targets
STAT6 (Signal Transducer and Activator of Transcription 6)
Beyond the preview
Go deeper on SIM0715.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SIM0715.